VYNE Therapeutics Inc (NASDAQ: VYNE) stock suffered a major decline of -11.0% on 11/29/23. The shares closed at $3.56. However, trading volume in this decline was exceptionally low at 9% of normal. The stock has performed in line with the market over the last nine months and has declined -9.9% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, VYNE is expected to continue to be a modest Value Eraser.
VYNE Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. VYNE Therapeutics has a slightly negative Power Rating of 34 and a very low Appreciation Score of 13, triggering the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment